Stryker Invests $400 Mn in CMR Surgical to Enter Soft Tissue Robotics Market

Announced on October 12, 2026, the partnership positions Stryker to compete in a market where Johnson & Johnson (J&J), Medtronic, and Intuitive Surgical are expanding their robotic-assisted surgery portfolios.

Stryker has invested approximately $400 million in CMR Surgical, securing exclusive US distribution rights for the company’s Versius robotic surgery system as it enters the soft tissue robotics market. The agreement also gives Stryker an exclusive option to acquire CMR Surgical’s remaining shares.

Announced on October 12, 2026, the partnership positions Stryker to compete in a market where Johnson & Johnson (J&J), Medtronic, and Intuitive Surgical are expanding their robotic-assisted surgery portfolios.

Cambridge, England-based CMR Surgical received US Food and Drug Administration (FDA) clearance for Versius to perform gallbladder procedures in 2025. By early 2026, the company had performed more than 45,000 procedures globally, according to J.P. Morgan analyst Robbie Marcus.

Stryker Expands Beyond Orthopedic Robotics

Stryker has established a presence in surgical robotics through its Mako system, which is used in orthopedic procedures. The company has been evaluating opportunities in soft tissue robotics for several years as competitors expand their presence in the segment.

Stifel analyst Rick Wise noted that the FDA clearances secured by J&J and Medtronic for their respective robotic systems have increased the urgency for Stryker to enter the market.

Stryker’s existing hospital equipment business and experience in robotics could support the commercialization of Versius in the United States. The company plans to use its distribution network to expand access to robotic-assisted surgery across hospitals and ambulatory surgery centers (ASCs).

Andy Pierce, Stryker’s group president for MedSurg and Neurotechnology, said the company selected CMR Surgical because of the opportunity to help healthcare providers expand robotic-assisted procedures across different care settings.

Versius Targets Hospitals and Ambulatory Surgery Centers

Versius features a modular design that allows its components to be moved between operating rooms. While its current US authorization covers gallbladder procedures, CMR plans to pursue additional indications for soft tissue surgery.

Under the agreement, Stryker will manage US sales and distribution, while CMR Surgical will continue leading commercial activities in other markets.

J.P. Morgan analyst Marcus suggested that Stryker and CMR could initially focus on lower-cost facilities, including ASCs, rather than directly challenging Intuitive Surgical’s da Vinci system in hospitals.

He expects the partnership to have a limited near-term effect on Intuitive’s US market position but could increase competitive pressure on Medtronic and J&J as more robotic surgery platforms enter the market.

The deal gives Stryker a route into soft tissue robotics while allowing CMR to leverage Stryker’s established commercial infrastructure in the United States.

Stay tuned for more such updates on Digital Health News